Kalaris Therapeutics reported total assets of $89.00M and total liabilities of $41.60M for the quarter ended Sep 2026, up 9.6% year over year. This balance sheet covers 30 quarters of results from Jun 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 201.66M | 100.21M | 71.09M | 123.83M | 106.09M | 115.70M | 196.95M | 95.63M | 90.12M | 5.23M | 6.24M | 1.91M | 1.64M | 100.97M | 88.43M | 42.39M | 98.05M | 34.43M | 43.17M | 47.38M | ||||||||||
| Short-term InvestmentsInvestments (Current) | 46.46M | 101.17M | 101.58M | 140.27M | 127.70M | 86.87M | 49.58M | 117.69M | 93.82M | 54.49M | 24.87M | 5.00M | 34.61M | 19.93M | 62.79M | 50.37M | 35.47M | |||||||||||||
| Cash & Current Investments | 248.12M | 201.40M | 172.70M | 264.10M | 233.80M | 202.60M | 246.50M | 213.30M | 183.90M | 140.50M | 129.60M | 121.90M | 118.30M | 100.97M | 88.43M | 0.08M | 118.00M | 104.90M | 93.50M | 82.90M | ||||||||||
| Receivables - OtherOther Receivables | 5.00M | |||||||||||||||||||||||||||||
| Current Deferred Tax AssetsCurrent Deferred Tax | -43.44M | |||||||||||||||||||||||||||||
| Prepaid Assets | 5.18M | 4.89M | 3.75M | 5.57M | 7.10M | 7.46M | 4.74M | 5.89M | 3.49M | 0.77M | 0.23M | 0.63M | 0.97M | 1.22M | 3.23M | 1.18M | 0.83M | 0.86M | 1.87M | 1.81M | ||||||||||
| Current Assets | 253.35M | 206.44M | 176.52M | 272.04M | 243.05M | 212.28M | 252.91M | 220.02M | 187.64M | 141.48M | 129.94M | 122.53M | 2.61M | 102.18M | 91.65M | 78.18M | 118.81M | 98.47M | 95.92M | 85.18M | ||||||||||
| Non-Current Assets | ||||||||||||||||||||||||||||||
| Construction in Progress | 24.87M | |||||||||||||||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 1.55M | 1.08M | 1.00M | 0.94M | 0.93M | 0.84M | 0.76M | 0.67M | ||||||||||||||||||||||
| Long-Term Investments | 7.65M | |||||||||||||||||||||||||||||
| Goodwill | 0.56M | |||||||||||||||||||||||||||||
| Intangibles | 1.94M | 1.83M | ||||||||||||||||||||||||||||
| Goodwill & Intangibles | 0.56M | 1.94M | 1.83M | |||||||||||||||||||||||||||
| Long-Term Deferred Tax | 62.31M | |||||||||||||||||||||||||||||
| Other Non-Current Assets | 1.95M | 1.83M | 1.71M | 1.59M | 1.46M | 1.34M | 1.54M | 2.28M | 0.97M | 0.55M | 0.55M | 3.56M | 0.91M | 1.19M | 1.48M | 1.45M | 2.25M | 2.23M | 2.48M | |||||||||||
| Non-Current Assets | 33.25M | 24.65M | 23.48M | 21.66M | 34.03M | 31.77M | 29.78M | 28.29M | 3.16M | 2.66M | 1.05M | 3.56M | 0.91M | 1.19M | 2.99M | 2.93M | 11.34M | 3.62M | 3.83M | |||||||||||
| Assets | 286.59M | 231.09M | 200.00M | 293.70M | 277.08M | 244.04M | 282.69M | 248.31M | 190.80M | 144.14M | 130.99M | 122.53M | 6.16M | 103.09M | 92.84M | 81.18M | 121.74M | 109.81M | 99.54M | 89.00M | ||||||||||
| Liabilities | ||||||||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||||||||
| Accounts Payables | 8.36M | 4.47M | 5.52M | 4.89M | 3.00M | 4.13M | 5.16M | 3.93M | 6.76M | 0.77M | 0.11M | 0.05M | 1.56M | 2.37M | 3.68M | 0.49M | 1.28M | 0.91M | 1.12M | 2.75M | ||||||||||
| Notes Payables | 6.59M | 2.36M | 2.24M | 1.92M | 7.17M | 8.27M | 8.48M | 12.98M | 10.78M | 2.30M | 0.67M | 19.54M | ||||||||||||||||||
| Payables | 14.95M | 6.83M | 7.76M | 6.81M | 10.17M | 12.40M | 13.65M | 16.90M | 17.54M | 3.06M | 0.78M | 0.05M | 21.10M | 2.37M | 3.68M | 0.49M | 1.28M | 0.91M | 1.12M | 2.75M | ||||||||||
| Accumulated Expenses | 20.15M | 10.08M | 13.12M | 13.68M | 13.99M | 12.29M | 16.73M | 15.92M | 10.09M | 4.60M | 1.58M | 1.36M | 2.20M | 2.51M | 3.97M | 5.20M | 8.12M | 6.86M | 7.27M | 5.44M | ||||||||||
| Other Accumulated Expenses | 1.29M | 0.39M | 0.63M | 0.73M | 0.83M | 1.04M | 0.30M | 0.46M | 1.03M | 0.27M | 0.04M | 0.08M | 0.66M | 1.89M | 2.50M | 3.59M | 4.30M | 5.35M | 5.90M | 3.73M | ||||||||||
| Current Leases | 0.00M | 0.00M | 0.00M | |||||||||||||||||||||||||||
| Current Taxes | 1.01M | 0.51M | 0.15M | 0.15M | 0.13M | 0.13M | 0.13M | |||||||||||||||||||||||
| Total Current Liabilities | 37.85M | 18.64M | 21.59M | 20.72M | 24.34M | 24.96M | 30.56M | 33.07M | 28.37M | 7.66M | 2.36M | 1.41M | 24.70M | 7.14M | 7.65M | 6.07M | 9.71M | 8.08M | 8.74M | 8.51M | ||||||||||
| Non-Current Liabilities | ||||||||||||||||||||||||||||||
| Preferred Stock Liabilities | 44.41M | 46.00M | 46.00M | 46.00M | 46.00M | |||||||||||||||||||||||||
| Operating Leases | 23.48M | 20.78M | 20.27M | 19.75M | 28.22M | 25.55M | 23.02M | 19.91M | 16.65M | 16.05M | 8.34M | 1.17M | 1.13M | 1.09M | 1.05M | 1.01M | ||||||||||||||
| Other Non-Current Liabilities | 32.04M | 32.08M | 32.08M | 32.08M | 32.08M | 32.08M | 32.08M | 32.08M | 32.08M | |||||||||||||||||||||
| Total Non-Current Liabilities | 179.87M | 70.70M | 7.14M | 7.65M | 7.23M | 10.85M | 9.17M | 9.79M | 9.53M | |||||||||||||||||||||
| Total Liabilities | 61.33M | 39.42M | 41.86M | 40.47M | 52.56M | 50.51M | 53.58M | 52.98M | 235.81M | 191.68M | 182.51M | 211.91M | 102.78M | 39.22M | 39.73M | 39.31M | 42.92M | 41.25M | 41.87M | 41.60M | ||||||||||
| Shareholder's Equity | ||||||||||||||||||||||||||||||
| Total Debt | 6.59M | 2.36M | 2.24M | 1.92M | 7.17M | 8.27M | 8.48M | 12.98M | 10.78M | 2.30M | 0.67M | 19.54M | -0.54M | -0.50M | ||||||||||||||||
| Common Equity | 225.27M | 191.68M | 158.14M | 253.23M | 224.52M | 193.53M | 229.11M | 195.33M | -45.02M | -47.54M | -51.53M | -89.38M | -96.62M | 63.87M | 53.12M | 41.87M | 78.81M | 68.56M | 57.67M | 47.40M | ||||||||||
| Liabilities and Shareholders Equity | 286.59M | 231.09M | 200.00M | 293.70M | 277.08M | 244.04M | 282.69M | 248.31M | 190.80M | 144.14M | 130.99M | 122.53M | 6.16M | 103.09M | 92.84M | 81.18M | 121.74M | 109.81M | 99.54M | 89.00M | ||||||||||
| Retained Earnings | -297.07M | -385.60M | -385.57M | -427.64M | -465.78M | -507.00M | -552.23M | -596.50M | -656.19M | -686.50M | -692.60M | -696.70M | -116.60M | -126.80M | -138.11M | -150.00M | -160.00M | -170.90M | -182.40M | -193.40M | ||||||||||
| Preferred Shares |
Pull Kalaris Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KLRS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KLRS", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KLRS&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();